From MXC ann. IHL expecting 3K bottles to come through for a big order in Q2 and already got >1K patients..
Should see similar revs in the Q2 4C? On top of oral devices of course...
Confusing as I am not sure if they meant 4500 unique patients per prescription or 4500 bottles prescribed...
After further research..
Looks like its around 800 patients as per their Jan 2020 Ann with 2K prescribed bottles...
They also acknowledge that the vast majority of prescriptions have been issued in Australia to date, meaning CannVaLate doing the majority of the distribution. I reckon that any pot stock selling oils has to partner w/ CannVaLate if not they wont get many patients at all.. All the bigger players including AGH in Aus are using CannVaLate to distribute.
MXC IMO isnt going anywhere anytime soon... But they have a MC of 37M as per the time of this post. Less patients than IHL, similar prescription numbers and lower patient numbers even... Where is this added value for IHL? Come on. Market asleep at the wheel.
